Table I.
Clinical characteristics of the hypersensitive patients
| Age (years)/ Gender |
Drug | Reaction | Time to reaction (days) |
Time since reaction (years) |
No. of courses prior to reaction |
LTT | |
|---|---|---|---|---|---|---|---|
| 1 | 18/M | Tazocin | MPE/Fevers | 9 | 7 | 3 | +++ |
| 2 | 29/F | Piperacillin | MPE | 7 | 12 | 11 | ++++ |
| 3 | 29/F | Tazocin | Fever/eosinophilia | 7 | 0.5 | 14 | ++ |
| 4 | 26/M | Tazocin | MPE | 5 | 2 | 3 | ++++ |
| 5 | 29/M | Tazocin | MPE | 3 | 5 | 4 | ++ |
| 6 | 24/F | Tazocin | Delayed angioedema | 6 | 3 | 4 | − |
| 7 | 17/M | Piperacillin | Flu-like illness | 2 | 5 | 3 | ++++ |
| 8 | 24/M | Piperacillin | MPE | 2 | >5* | NA | +++ |
| 9 | 23/M | Tazocin | MPE | 11 | 4 | 9 | +++ |
| 10 | 30/F | Tazocin | Flu-like illness | 3 | 1 | 9 | ++ |
| 11 | 45/F | Tazocin | Fevers | 11 | 5 | 14 | − |
| 12 | 19/M | Tazocin | MPE/fever | 2 | 0.5 | 4 | ++++ |
| 13 | 22/F | Tazocin | MPE | 7 | 5 | 6 | ++ |
| 14 | 21/F | Tazocin | Arthralgia | 5 | 4 | 4 | ++++ |
| 15 | 17/M | Tazocin | MPE | 4 | 6 | 11 | − |
| 16 | 24/F | Tazocin | Arthralgia/MPE | 7 | 2 | 7 | + |
| 17 | 22/M | Tazocin | Pruritis | 5 | 4 | 11 | + |
| 18 | 28/F | Tazocin | Fever/arthralgia | 9 | 6 | 7 | +++ |
| 19 | 31/F | Tazocin | Flu-like illness | 9 | 6 | 12 | + |
| 20 | 34/M | Piperacillin | MPE | 2 | 10 | 11 | − |
| 21 | 32/M | Piperacillin | MPE | 5 | 10 | 8 | + |
| 22 | 23/F | Tazocin | Fevers/unwell | 5 | 3 | 12 | + |
| 23 | 29/M | Tazocin | Tight chest | 4 | 6 | 9 | − |
| 24 | 18/M | Piperacillin | Urticarial rash | 2 | >5* | NA | − |
| 25 | 40/M | Piperacillin | Fevers | 10 | 12 | 11 | − |
| 26 # | 29/F | Piperacillin | MPE | 4 | 5 | 9 | − |
| 27 # | 34/F | Tazocin | MPE | 3 | 1 | 17 | − |
| 28 # | 35/F | Piperacillin | MPE | 7 | 10 | 17 | − |
F: female; M: male; MPE: maculopapular exanthema; NT: not tested; ID: intradermal; LTT: lymphocyte transformation test.
+: SI 2-5; ++: SI 5-10; +++: SI 10-20; ++++: >20
*
Indicates that the exact time period since reaction is not known due to missing medical records or occurrence at another cystic fibrosis centre.
#
Indicates that patient on long-term immunosuppressive therapy. Patients 26 and 27 were receiving hydroxychloroquine for cystic fibrosis related arthritis. Patient 28 received long term low dose steroids as prophylaxis against hypersensitive bronchopulmonary aspergillosis.